Glaxosmithkline Pharmaceuticals has informed about a meeting of the Board of Directors of the Company was held today i.e. 4th February, 2019. Pursuant to Clause 33 read with Clause 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, the Company has enclosed herewith the Un-Audited Standalone Financial Results and Limited Review Report for the quarter and nine months ended 31st December, 2018. Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, the Board of Directors at its meeting held today have re-appointed Annaswamy Vaidheesh (DIN No: 01444303) as Managing Director of the Company for period from 1st October, 2019 to 31st March 2020. A Brief profile of Annaswamy Vaidheesh is enclosed as Annexure.
The above information is a part of company’s filings submitted to BSE.
